Skip to main content

Table 1 Patient and treatment characteristics

From: Phase I trial of dose-escalated stereotactic radiosurgery (SRS) boost for unfavorable locally advanced oropharyngeal cancer

Characteristic No. of patients (%) (N = 34)
Age (mean) 60 years
Smoking history (median) 35 pack-years
Gender  
 Male 27 (79%)
 Female 7 (21%)
AJCC 7th edition Stage  
 III 3 (9%)
 IVa 28 (82%)
 IVb 3 (9%)
AJCC 8th edition stage  
 II (P16 positive) 17 (50%)
 III (P16 positive) 4 (12%)
 III (p16 negative) 3 (9%)
 IVa (p16 negative) 10 (29%)
T Classification  
 T1 2 (6%)
 T2 15 (44%)
 T3 11 (32%)
 T4a 5 (15%)
 T4b 1 (3%)
N Classification  
 N0 1 (3%)
 N1 5 (15%)
 N2a 5 (15%)
 N2b 14 (41%)
 N2c 9 (26%)
Primary site  
 Tonsil 19 (56%)
 Base of tongue 13 (38%)
 Pharyngeal wall 1 (3%)
 Soft palate 1 (3%)
Mean boost volume 54 cc (range 13–185 cc)
 8 Gy SRS boost 11 (32%)
 10 Gy SRS boost 16 (47%)
 5 Gy × 2 SRS boost 7 (21%)
HPV status  
 HPV-positive smokers 21 (62%)
 HPV-negative 13 (38%)
Chemotherapy  
 Cisplatin 27 (79%)
 Cetuximab 1 (3%)
 Carboplatin paclitaxel 1 (3%)
 Cisplatin followed by carboplatin and paclitaxel 4 (12%)
 Unknown 1 (3%)